Keywords: azd0837, comparable, profile, vkas, ph, ii, study

AZD0837 "comparable" profile to VKAs in Ph II study

Article | 30 March 2009

Print This

Data presented at the annual meeting of the American College of Cardiology in Florida, show that Anglo-Swedish drug major AstraZeneca's ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in